Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus MAFENIDE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus MAFENIDE ACETATE.
BACTROBAN vs MAFENIDE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Mafenide acetate is a sulfonamide antibiotic that inhibits bacterial folic acid synthesis by competitively antagonizing para-aminobenzoic acid (PABA), thereby preventing bacterial growth. It has broad-spectrum activity against gram-negative and gram-positive organisms, including Pseudomonas aeruginosa.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Apply topically as a thin layer to affected areas once or twice daily. The dosage form is an 11.1% cream or solution. The cream is applied using a sterile gloved hand; the solution is applied with a sterile spray or brush.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Approximately 45 minutes (range 30-60 minutes) for the parent compound; the metabolite p-CBS has a longer half-life of about 4 hours.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Renal: approximately 80% excreted unchanged in urine; the remainder is metabolized to p-carboxybenzene sulfonamide (p-CBS) which is also renally excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic